MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
0.690
-0.020 (-2.80%)
Nov 21, 2024, 10:58 AM EST - Market open

MiNK Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
-----0.69
Gross Profit
-----0.69
Selling, General & Admin
6.337.437.834.641.293.83
Research & Development
11.1315.4923.1213.979.5119.65
Operating Expenses
17.4622.9230.9518.6110.823.48
Operating Income
-17.46-22.92-30.95-18.61-10.8-22.79
Interest Expense
----2.43-2.44-1.56
Interest & Investment Income
0.20.460.25---
Currency Exchange Gain (Loss)
----0.410.490.04
Other Non Operating Income (Expenses)
-0.02-0-0.090.630.350
EBT Excluding Unusual Items
-17.27-22.46-30.78-20.82-12.4-24.31
Other Unusual Items
--2.79-9.4-3.840.51
Pretax Income
-17.09-22.46-27.99-30.21-16.24-23.8
Net Income
-17.09-22.46-27.99-30.21-16.24-23.8
Net Income to Common
-17.09-22.46-27.99-30.21-16.24-23.8
Shares Outstanding (Basic)
353434262424
Shares Outstanding (Diluted)
353434262424
Shares Change (YoY)
3.60%2.04%29.38%7.95%0.20%-
EPS (Basic)
-0.49-0.65-0.83-1.16-0.67-0.99
EPS (Diluted)
-0.49-0.65-0.83-1.16-0.67-0.99
Free Cash Flow
-12.1-15.84-19.12-13.08-8.43-15.37
Free Cash Flow Per Share
-0.34-0.46-0.57-0.50-0.35-0.64
Gross Margin
-----100.00%
Operating Margin
------3305.06%
Profit Margin
------3451.46%
Free Cash Flow Margin
------2228.86%
EBITDA
-17.25-22.72-30.83-18.53-10.74-22.76
D&A For EBITDA
0.210.20.120.080.060.04
EBIT
-17.46-22.92-30.95-18.61-10.8-22.79
Source: S&P Capital IQ. Standard template. Financial Sources.